Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reply to letter to editor: Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Kaushal M, Razak A, Patel W, Pullattayil AK, Kaushal A. Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol. 2020. https://doi.org/10.1038/s41372-020-00884-9.

  2. 2.

    Fan YY, Huang YS, Huang CY, Hsu JF, Shih CP, Hwang YS, et al. Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study. Ophthalmology. 2019;126:1567–77.

  3. 3.

    Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E, et al. Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PLoS ONE. 2020;15:e0230678.

    CAS  Article  Google Scholar 

  4. 4.

    Rodriguez SH, Peyton C, Lewis K, Andrews B, Greenwald MJ, Schreiber MD, et al. Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP. Ophthalmic Surg Lasers Imaging Retina. 2019;50:337–43.

  5. 5.

    Anand N, Blair MP, Greenwald MJ, Rodriguez SH. Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP. J AAPOS. 2019;23:88E1–6.

    Article  Google Scholar 

  6. 6.

    Kennedy KA, Mintz-Hittner HA. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS. 2018;22:61–65.e1.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Abdul Razak.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Razak, A., Kaushal, M. Reply to letter to editor: Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol (2021). https://doi.org/10.1038/s41372-021-01127-1

Download citation

Search

Quick links